Problems of VirologyProblems of VirologyВопросы вирусологии0507-40882411-2097Central Research Institute for Epidemiology12095ArticlesСтатьиSpecific humoral immunity after single immunization with mumps vaccine: data of a 3-year follow-upСостояние специфического гуморального иммунитета после однократной иммунизации паротитной вакциной: данные 3-летнего наблюдения15062011563NO3 (2011)№3 (2011)454809062023Copyright ©; 2011, Otrashevskaya E.V., Bukin E.K., Krasil'nikov I.V., Ignat'ev G.M., Atrasheuskaya A.V., Bukin E.K., Krasilnikov I.V., Ignatyev G.M.Copyright ©; 2011, Отрашевская Е.В., Букин Е.К., Красильников И.В., Игнатьев Г.М., Atrasheuskaya A.V., Bukin E.K., Krasilnikov I.V., Ignatyev G.M.2011Otrashevskaya E.V., Bukin E.K., Krasil'nikov I.V., Ignat'ev G.M., Atrasheuskaya A.V., Bukin E.K., Krasilnikov I.V., Ignatyev G.M.Отрашевская Е.В., Букин Е.К., Красильников И.В., Игнатьев Г.М., Atrasheuskaya A.V., Bukin E.K., Krasilnikov I.V., Ignatyev G.M.https://creativecommons.org/licenses/by/4.0https://virusjour.crie.ru/jour/article/view/12095

The level and spectrum of humoral specific immunity were studied in 60 volunteers immunized with Russian mumps vaccine. Specific IgG levels were measured by enzyme immunoassay (EIA) and neutralization test using the Leningrad-3 (L-3) mumps virus (MV) vaccine strain and 5 heterologous MV strains of various genotypes (A, B, C, D, and H). The maximum functional activity of antibodies was recorded at an average of 18 months postvaccination. Within 3 years after vaccination, starting at 6 months, specific IgG neutralized all 6 MV strains having varying activity in relation to the genotype. Neutralizing titers (NT) against the L-3 strain were 1.3-1.7-fold higher than those against heterologous MV strains throughout the follow-up. Despite a tendency towards lower specific IgG levels, within 3 years postvaccination, EIA IgG titers remained to be 2.5 -log, L-3 strain HT were -log2 or more, and the titers against 5 heterologous MV strains were 2 -log2 or more in all the volunteers.

Изучены уровень и спектр гуморального специфического иммунитета у 60 добровольцев, привитых российской паротитной вакциной. Уровень специфических IgG измеряли в иммуноферментной реакции (ИФА) и в реакции нейтрализации (РН) с вакцинным штаммом Ленинград-3 (Л-3) вируса паротита (ВП) и с 5 гетерологичными штаммами ВП разных генотипов (А, В, С, D и Н). Максимум функциональной активности гуморального иммунитета был зарегистрирован в среднем на 18-й месяц после вакцинации. В течение 3 лет после вакцинации, начиная с 6-го месяца, специфические IgG нейтрализовали все 6 штаммов ВП с разной степенью активности в зависимости от генотипа. Нейтрализующие титры (НТ) к штамму Л-3 были в 1,3- 1,7 раза выше титров к гетерологичным штаммам ВП на протяжении всего периода наблюдения. Несмотря на тенденцию к снижению уровня специфических IgG, у всех добровольцев в течение 3 лет после вакцинации титры IgG в ИФА сохранились на уровне выше 2,5-lg, НТ к штамму Л-3 3-log2 и выше, а титры к 5 гетерологичным штаммам ВП - от 2-log2.

Leningrad-3spectrum of neutralizing antibody activityavidityЛенинград-3спектр нейтрализующей активности антителавидностьAtrasheuskaya A. V., Neverov A. A., Rubin S. S., Ignatyev G. M. Horizontal transmission of the L-3 live attenuated mumps vaccine virus // Vaccine. - 2006. - Vol. 24. - P. 1530-1536.Atrasheuskaya A. V., Blatun E. M., Kulak M. V. et al. Investigation of mumps vaccine failures in Minsk, Belarus // Vaccine. - 2007. - Vol. 25. - P. 4651-4658.Atrasheuskaya A. V., Kulak M. V., Rubin S., Ignatyev G. M. Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004 // Clin. Microbiol. Infect. - 2007. - Vol. 13. - P. 670-676.Date A. A., Kyaw M. H., Rue A. M. et al. Long-term persistence of mumps antibody after receipt of 2 MMR vaccinations and antibody response after a third MMR vaccination among a university population // J. Infect. Dis. - 2008. - Vol. 197. - P. 1662-1668.Davidkin I., Jokinen S., Broman M. et al. Persistence of measles, mumps and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow up // J. Infect. Dis. - 2008. - Vol. 197. - P. 950-956.Dayan G. H., Rubin S. Mumps outbreaks in vaccinated populations; are available mumps vaccine effective enough to prevent outbreaks? // Clin. Infect. Dis. - 2008. - Vol. 47. - P. 1458- 1467.Ennis F. A. Immunity to mumps an institutional epidemic: correlation of insusceptibility to mumps with serum plague neutralizing and hemagglutination-inhibiting antibodies // J. Infect. Dis. - 1969. - P. 323-329.Hanna-Wakima R., Yasukawa L. L., Sung P. et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood // J. Infect. Dis. - 2008. - Vol. 197, N 12. - P. 1669-1675.Ivancic-Jelecki J., Santak M., Forcic D. Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains // Infect., Genet., Evol. - 2008. - Vol. 8, N 5. - P. 603-613.Jokinen S., Osteriund P., Julkunen I., Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination // J. Infect. Dis. - 2007. - Vol. 196, N 6. - P. 861-867.Narita M., Matsuzono Y., Takekoshi Y. et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G // Clin. Diagn. Lab. Immunol. - 1998. - Vol. 5, N 6. - P. 799-803.Nöjd J., Tecle T., Samuelsson A., Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype// Vaccine. - 2001. - Vol. 19. - P. 1727-1731.Norman G. R., Streiner D. L. Biostatistics. The bare essentials. - 2-nd Ed. - London, 2000. - P. 324.Orvell C., Alsheikhly A.-R., Kalantari M., Johansson B. Characterization of genotype-specific epitopes of the HN protein of mumps virus // J. Gen. Virol. - 1997. - Vol. 8. - P. 3187- 3193.Paunio M., Hedman K., Davidkin I., Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy // Expert Opin. Pharmacother. - 2003. - Vol. 4, N 8. - P. 1215-1225.Peltola H., Kulkarni P. S., Kapre S. V. et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines // Clin. Infect. Dis. - 2007. - Vol. 45. - P. 459-466.Pipkin P. A., Afzal M. A., Heath A. B. et al. Assay of humoral immunity to mumps virus // J. Virol. Meth. - 1999. - Vol. 79. - P. 219-225.Rubin S., Mauldin J., Chumakov K. et al. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains // Vaccine. - 2006. - Vol. 24. - P. 2662-2668.Rubin S. A., Qi L., Audet S. A. et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak // J. Infect. Dis. - 2008. - Vol. 198, N 4. - P. 508-515.WHO-recommended standards for surveillance of selected vaccine-preventable diseases // Vaccines and Biologicals. - Geneva, 2003. - P. 18-20.